The nitric oxide (NO) metabolites in monitoring and therapy of bronchial asthma Source: Annual Congress 2011 - Bronchial hyperresponsiveness and exhaled and sputum biomarkers Year: 2011
The experience of monitoring the exhaled nitric oxide (FeNO) during the anti-IgE-therapy (omalizumab) in children with uncontrolled severe asthma Source: International Congress 2015 – Exhaled biomarkers in monitoring airways disease Year: 2015
Dynamics of the nitric oxide metabolites in the exhaled breath condensate (EBC) in atopic asthma (BA) children receiving various treatment options Source: Annual Congress 2013 –Monitoring asthma: genes, cells and molecules Year: 2013
Changes in nitric oxide production in patients with COPD Source: Eur Respir J 2006; 28: Suppl. 50, 190s Year: 2006
Changes of exhaled nitric oxide during steroid treatment of childhood asthma Source: Eur Respir J 2002; 19: 1015-1019 Year: 2002
Non-adherence to inhaled corticosteroid therapy as an explanation for persistently elevated exhaled nitric oxide levels in patients with asthma: Effect of directly observed therapy with inhaled corticosteroids (DOT-ICS) Source: International Congress 2015 – Exhaled biomarkers in monitoring airways disease Year: 2015
Relationship between baseline fraction of exhaled nitric oxide (FeNO) and response to anti-IL-5/5R therapies in severe eosinophilic asthma (SEA) Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020
Stability of exhaled nitric oxide (FE NO) in patients with severe, steroid-dependent asthma Source: Annual Congress 2008 - Clinical utility of exhaled nitric oxide measurement Year: 2008
The cycle of the nitric oxide metabolism in patients with COPD and chronic cerebrovascular diseases (CCVD) Source: Annual Congress 2013 –The vulnerable patient and ageing cells Year: 2013
Salt chamber treatment had no effect on fractional exhaled nitric oxide (FeNO) in patients with symptoms suggesting asthma Source: Annual Congress 2008 - Comorbid cardiovascular condition and therapy of asthma Year: 2008
Utility of fractional exhaled nitric oxide (FeNO) in assessing asthma control following inhaled corticosteroid treatment Source: International Congress 2016 – Assessing lower airway inflammation with different tools Year: 2016
Fractional exhaled nitric oxide (FeNO) suppression with directly observed inhaled corticosteroid therapy: does it make a difference to patient outcomes? Source: International Congress 2018 – Clinical and functional monitoring in airway disease Year: 2018
Changes in nitric oxide production in patients with bronchial asthma Source: Eur Respir J 2007; 30: Suppl. 51, 588s Year: 2007
Comparison of hemodynamic effects of inhaled nitric oxide (iNO) and inhaled epoprostenol (iEPO) in patients with pulmonary hypertension (PH) Source: Annual Congress 2011 - Treatment of pulmonary hypertension Year: 2011
The clinical utility of exhaled nitric oxide (eNO) in asthma, the first 1,000 patients Source: Eur Respir J 2004; 24: Suppl. 48, 304s Year: 2004
Adult asthma, fraction of exhaled nitric oxide (FENO ), and lung function Source: Annual Congress 2009 - Epidemiology of asthma Year: 2009
Increased nitric oxide synthase isoforms, endothelin 1 and apoptosis varied in lungs from patients with (SSc) and had impact on pulmonary function tests Source: Annual Congress 2010 - Biomarkers in diffuse parenchymal lung disease Year: 2010
Increased expression of inducible nitric oxide synthase (iNOS) in peripheral lung of severe COPD patients Source: Eur Respir J 2002; 20: Suppl. 38, 95s Year: 2002
Sputum neutrophilia is correlated with levels of exhaled nitric oxide (NO) in patients with chronic, stable sarcoidosis Source: Eur Respir J 2001; 18: Suppl. 33, 344s Year: 2001
Exhaled nitric oxide predicts control in patients with difficult-to-treat asthma Source: Eur Respir J 2010; 35: 1221-1227 Year: 2010